Your browser doesn't support javascript.
loading
Kawasaki Disease in the Time of COVID-19 and MIS-C: The International Kawasaki Disease Registry.
Harahsheh, Ashraf S; Shah, Samay; Dallaire, Frederic; Manlhiot, Cedric; Khoury, Michael; Lee, Simon; Fabi, Marianna; Mauriello, Daniel; Tierney, Elif Seda Selamet; Sabati, Arash A; Dionne, Audrey; Dahdah, Nagib; Choueiter, Nadine; Thacker, Deepika; Giglia, Therese M; Truong, Dongngan T; Jain, Supriya; Portman, Michael; Orr, William B; Harris, Tyler H; Szmuszkovicz, Jacqueline R; Farid, Pedrom; McCrindle, Brian W.
Afiliación
  • Harahsheh AS; Division of Cardiology, Department of Pediatrics, Children's National Hospital; George Washington University School of Medicine and Health Sciences; Washington, DC, USA. Electronic address: aharahsh@childrensnational.org.
  • Shah S; George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • Dallaire F; Department of Paediatrics, Université de Sherbrooke, and Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada.
  • Manlhiot C; Blalock-Taussig-Thomas Congenital Heart Center at Johns Hopkins University, Baltimore, Maryland, USA.
  • Khoury M; Division of Paediatric Cardiology, Department of Paediatrics, University of Alberta, Edmonton, Alberta, Canada.
  • Lee S; The Heart Center at Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Fabi M; Paediatric Emergency Unit, IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy.
  • Mauriello D; Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, USA.
  • Tierney ESS; Department of Pediatrics, Division of Cardiology, Lucile Packard Children's Hospital, Stanford University Medical Center, Palo Alto, California, USA.
  • Sabati AA; Phoenix Children's Hospital, Phoenix, Arizona, USA.
  • Dionne A; Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Dahdah N; Division of Paediatric Cardiology, CHU Ste-Justine, University of Montréal, Montréal, Québec, Canada.
  • Choueiter N; Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Thacker D; Nemours Children's Hospital, Wilmington, Delaware, USA.
  • Giglia TM; Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Truong DT; University of Utah and Primary Children's Hospital, Salt Lake City, Utah, USA.
  • Jain S; New York Medical College/Maria Fareri Children's Hospital at Westchester Medical Center, Valhalla, New York, USA.
  • Portman M; Seattle Children's Hospital, Seattle, Washington, USA.
  • Orr WB; Division of Pediatric Cardiology, Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri, USA.
  • Harris TH; UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Szmuszkovicz JR; Children's Hospital of Los Angeles, Los Angeles, California, USA.
  • Farid P; Labatt Family Heart Centre, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
  • McCrindle BW; Labatt Family Heart Centre, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Can J Cardiol ; 40(1): 58-72, 2024 01.
Article en En | MEDLINE | ID: mdl-37290536
BACKGROUND: Patients with multisystem inflammatory syndrome in children (MIS-C) and Kawasaki disease (KD) have overlapping clinical features. We compared demographics, clinical presentation, management, and outcomes of patients according to evidence of previous SARS-CoV-2 infection. METHODS: The International Kawasaki Disease Registry (IKDR) enrolled KD and MIS-C patients from sites in North, Central, and South America, Europe, Asia, and the Middle East. Evidence of previous infection was defined as: Positive (household contact or positive polymerase chain reaction [PCR]/serology), Possible (suggestive clinical features of MIS-C and/or KD with negative PCR or serology but not both), Negative (negative PCR and serology and no known exposure), and Unknown (incomplete testing and no known exposure). RESULTS: Of 2345 enrolled patients SARS-CoV-2 status was Positive for 1541 (66%) patients, Possible for 89 (4%), Negative for 404 (17%) and Unknown for 311 (13%). Clinical outcomes varied significantly among the groups, with more patients in the Positive/Possible groups presenting with shock, having admission to intensive care, receiving inotropic support, and having longer hospital stays. Regarding cardiac abnormalities, patients in the Positive/Possible groups had a higher prevalence of left ventricular dysfunction, and patients in the Negative and Unknown groups had more severe coronary artery abnormalities. CONCLUSIONS: There appears to be a spectrum of clinical features from MIS-C to KD with a great deal of heterogeneity, and one primary differentiating factor is evidence for previous acute SARS-CoV-2 infection/exposure. SARS-CoV-2 Positive/Possible patients had more severe presentations and required more intensive management, with a greater likelihood of ventricular dysfunction but less severe coronary artery adverse outcomes, in keeping with MIS-C.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Síndrome de Respuesta Inflamatoria Sistémica / COVID-19 / Síndrome Mucocutáneo Linfonodular Tipo de estudio: Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Can J Cardiol Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Síndrome de Respuesta Inflamatoria Sistémica / COVID-19 / Síndrome Mucocutáneo Linfonodular Tipo de estudio: Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Can J Cardiol Asunto de la revista: CARDIOLOGIA Año: 2024 Tipo del documento: Article